Full-Time
Posted on 12/6/2025
Healthcare, insurance, PBM, and retail pharmacy
$66.6k - $142.6k/yr
Company Historically Provides H1B Sponsorship
Cary, IL, USA + 2 more
More locations: Johnsburg, IL, USA | Crystal Lake, IL, USA
In Person
CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Woonsocket, Rhode Island
Founded
1963
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Company Equity
Wellness Program
Professional Development Budget
Paid Vacation
Paid Holidays
CVS Health has opened its first pharmacy-only location in Chicago, part of plans to launch nearly 20 such sites across the US this year. The 3,000-square-foot store at 2628 West Pershing Road features a full-service pharmacy with selected over-the-counter products. The pharmacy-only format is designed to increase access to medications, immunizations and pharmacist consultations in underserved communities. Additional locations are planned for Houston, Roxbury, Detroit and Brooklyn in 2026, alongside more than 40 traditional CVS Pharmacy stores. The move responds to consumer preferences, with CVS's 2025 research showing 80% of patients prefer face-to-face pharmacy care and 48% would switch pharmacies if limited to digital-only options. The company opened its first pharmacy-only site in Birmingham, Alabama, late last year.
CVS Health has reached a proposed settlement with the Federal Trade Commission over insulin pricing practices at its Caremark pharmacy benefit manager unit. The company also declared a quarterly dividend of $0.665 per share, payable on 4 May 2026. The settlement places CVS's pharmacy benefit management model under increased regulatory scrutiny regarding drug cost transparency. The company's investment narrative centres on its integrated model across insurance, pharmacy and care delivery, with near-term focus on restoring profitability in healthcare delivery and PBM services. CVS recently appointed former Elevance Health CFO John E. Gallina to its board as an audit committee financial expert. The company's narrative projects $445.5 billion revenue and $10.2 billion earnings by 2029, implying a fair value of $96.50 per share.
Bernstein analyst Lance Wilkes upgraded CVS Health to "Outperform" from "Market Perform" on 12 March, raising the price target to $94 from $91. The upgrade reflects the company's attractive exposure to the Medicare Advantage turnaround and expectations of stable earnings in its pharmacy and pharmacy benefit manager businesses following reforms. Wilkes cited the PBM bill passage and the Federal Trade Commission settlement with Cigna as clearing events for the stock. Separately, CVS Health announced a strategic partnership with Google Cloud focused on reimagining healthcare experiences through its new health technology subsidiary, Health100, which will offer AI-powered healthcare services. CVS Health operates as a diversified healthcare company combining insurance, pharmacy benefit management, retail pharmacies and clinical services across the United States.
Aetna, a CVS Health subsidiary, has agreed to pay $117.7 million to the US Department of Justice to settle allegations that it submitted inaccurate diagnosis codes for Medicare Advantage members to increase reimbursements. The settlement resolves longstanding False Claims Act allegations related to the Medicare Advantage programme. CVS Health shares recently closed at $76.07, down 5.1% year-to-date, though up 20.1% over the past year. The settlement is material for the company, which has thin net margins of 0.4% and debt not well covered by operating cash flow. The agreement highlights compliance risks in CVS Health's government-facing insurance operations, a central part of its Medicare Advantage business. Analysts' average target price stands at $96.50, approximately 27% above current levels.
Alphabet faces a wrongful death lawsuit alleging its Gemini AI chatbot contributed to a user's suicide, reportedly the first legal case directly linking Google's AI tools to a death. Simultaneously, the company announced a healthcare AI partnership with CVS Health focused on a real-time consumer engagement platform. The contrasting developments underscore Alphabet's expanding role in high-stakes sectors. The CVS collaboration integrates Gemini into Health100, a platform handling personal interactions across insurers, pharmacies and care providers. Meanwhile, the lawsuit tests whether conversational AI design and crisis protocols carry a duty of care, even outside formal healthcare settings. For investors, the key questions centre on how Alphabet manages legal risk, establishes guardrails and navigates regulatory oversight as its AI tools penetrate sectors requiring heightened safety and compliance standards.